COSM Stock Overview Manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cosmos Health Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cosmos Health Historical stock prices Current Share Price US$0.86 52 Week High US$1.58 52 Week Low US$0.47 Beta 3.18 1 Month Change 30.70% 3 Month Change 8.20% 1 Year Change -20.61% 3 Year Change -99.05% 5 Year Change -98.35% Change since IPO -99.46%
Recent News & Updates
Cosmos Health Inc. Appoints Dimitrios Trafalis as Head of Oncology at the Company's Research and Development division Dec 27 Cosmos Health Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Dec 19
New major risk - Shareholder dilution Nov 22
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 17
Cosmos Health Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Nov 13
Cosmos Health Inc., Annual General Meeting, Nov 19, 2024 Oct 02 See more updates
Cosmos Health Inc. Appoints Dimitrios Trafalis as Head of Oncology at the Company's Research and Development division Dec 27 Cosmos Health Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Dec 19
New major risk - Shareholder dilution Nov 22
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 17
Cosmos Health Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Nov 13
Cosmos Health Inc., Annual General Meeting, Nov 19, 2024 Oct 02
Cosmos Health Inc. Provides Earnings Guidance for the Year 2024, 2025, 2026, 2027 Sep 19
Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements Aug 24
Positive Sentiment Still Eludes Cosmos Health Inc. (NASDAQ:COSM) Following 26% Share Price Slump Aug 16
Cosmos Health Inc. announced delayed 10-Q filing Aug 16
Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of its Forms 10-K and 10-Q May 29 Cosmos Health Inc. announced delayed 10-Q filing May 18
Cosmos Health Inc. announced delayed annual 10-K filing Apr 03
Cosmos Health Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price Mar 25
Cosmos Health Inc. Commences Development of Cloudscreen 2.0 the New Iteration of Its Next Generation AI Drug Repurposing Platform Mar 22
Cosmos Health Inc. Receives Regulatory Approval to Sell Sky Premium Life Products in UAE Nutritional Supplements Market Mar 21
New major risk - Financial position Mar 08 Cosmos Health Inc. has filed a Follow-on Equity Offering in the amount of $5.049535 million. Mar 01
Slammed 27% Cosmos Health Inc. (NASDAQ:COSM) Screens Well Here But There Might Be A Catch Feb 23
High number of new and inexperienced directors Feb 14
Cosmos Health Inc. (NasdaqCM:COSM) completed the acquisition of Cloudscreen. Jan 24
Cosmos Health Inc. announced delayed 10-Q filing Nov 15
High number of new and inexperienced directors Nov 15
Cosmos Health Inc. (NasdaqCM:COSM) signed an agreement to acquire Cloudscreen. Oct 13
Cosmos Health Inc. Announces Executive and Board Changes Sep 23 Cosmos Health Inc. Provides Earnings Guidance for the Year 2023 Sep 15
Cosmos Health Inc., Annual General Meeting, Sep 18, 2023 Sep 06
Cosmos Health Inc. announced delayed 10-Q filing Aug 17
Second quarter 2023 earnings released: US$0.091 loss per share (vs US$23.37 loss in 2Q 2022) Aug 17 Cosmos Health Inc. announced that it has received $5.25 million in funding Jul 28
Cosmos Holdings Inc. (NasdaqCM:COSM) acquired 100% stakes in Cana Laboratories S.A. for approximately $1.67 million. Jul 07
Cosmos Health Inc. Launches Terra Creta Jun 15
Cosmos Health Inc. entered into letter of intent agreement to acquire Docpharm Arzneimittelvertrieb Gmbh & Co. Kg Auf Aktien. May 26 Cosmos Health Inc. announced delayed 10-Q filing May 17
Full year 2022 earnings released: US$33.16 loss per share (vs US$23.74 loss in FY 2021) Apr 13
Cosmos Health Inc. Appoints Nikos Bardakis as Chief Operating Officer Feb 02
Cosmos Health Inc. (NasdaqCM:COSM) announces an Equity Buyback for $3 million worth of its shares. Jan 25 Cosmos Health Inc. announced that it has received $32.52568 million in funding Cosmos Health Inc. announced that it has received $32.52568 million in funding Dec 23
Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million. Dec 21
Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million. Dec 20
Chairman & CEO exercised options to buy US$605k worth of stock. Dec 03
Cosmos Health Enters the Development Phase for CCX0722, an Innovative Product for Obesity and Weight Management Dec 02
Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.11 loss in 3Q 2021) Nov 16
Cosmos Holdings Inc., Annual General Meeting, Dec 02, 2022 Oct 21 Cosmos Holdings Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. Oct 19
Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a non-binding letter of intent agreement to acquire ZipDoctor, Inc from American International Holdings Corp. (OTCPK:AMIH). Sep 29
Cosmos Holdings intends to acquire telemedicine platform ZipDoctor Sep 28
Cosmos Holdings reports Q2 results Aug 22
Cosmos Holdings Inc. announced delayed 10-Q filing Aug 17
Cosmos Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Jul 30
Cosmos changes name to Cosmos Healthto Jul 29
Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a binding letter of intent to acquire Cana Laboratories S.A. Jul 21
Cosmos climbs 11% on Cana Laboratories acquisition, expanding product line and integrating vertically Jul 20
Cosmos Holdings, Inc. Appoints Dr. Panagiotis Zoumpoulakis to its Advisory Board Jul 09
Cosmos Holdings Inc. (NasdaqCM:COSM) entered into an agreement to acquire product portfolio of Life NLB, Ltd. Jul 08
Cosmos Holdings to acquire bone health product portfolio from LIFE NLB Jul 06
Cosmos Holdings Inc. announced delayed 10-Q filing May 18
Cosmos Holdings Inc. announced delayed annual 10-K filing Apr 01
Cosmos Holdings Inc. announced delayed annual 10-K filing Apr 03
Cosmos Holdings, Inc. Launches Osteodome in EU Feb 12
Cosmos Holdings Inc. Launches New Proprietary Enhanced Dietary Supplement Jan 12
Cosmos Holdings Inc. Appoints Georgios Terzis as Chief Financial Officer Nov 18 Shareholder Returns COSM US Healthcare US Market 7D 38.7% 0.7% 3.2% 1Y -20.6% -4.0% 24.0%
See full shareholder returns
Return vs Market: COSM underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is COSM's price volatile compared to industry and market? COSM volatility COSM Average Weekly Movement 10.9% Healthcare Industry Average Movement 8.0% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: COSM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: COSM's weekly volatility (11%) has been stable over the past year.
About the Company Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Show more Cosmos Health Inc. Fundamentals Summary How do Cosmos Health's earnings and revenue compare to its market cap? COSM fundamental statistics Market cap US$17.55m Earnings (TTM ) -US$33.81m Revenue (TTM ) US$56.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) COSM income statement (TTM ) Revenue US$56.04m Cost of Revenue US$51.50m Gross Profit US$4.54m Other Expenses US$38.35m Earnings -US$33.81m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.61 Gross Margin 8.10% Net Profit Margin -60.34% Debt/Equity Ratio 29.4%
How did COSM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/17 05:44 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cosmos Health Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Howard Halpern Taglich Brothers, Inc.
Show 0 more analysts 
